EMA Panel Backs Adalimumab Biosimilar Amsparity
The CHMP has recommended approval of Pfizer’s adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children. International Approvals …read more
Outcomes in TN Breast Cancer Predicted by Blood Biomarkers
Biomarkers of residual disease at surgery identify which triple-negative breast cancer patients already treated with neoadjuvant therapy will do well and which will do poorly over the next 2 years. Medscape Medical News …read more